NEWS

Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients

  • 2021.01.08
  • NEWS RELEASE

Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients.

 

For detailed information, see the below URL.

https://www.chemomab.com/uploads/pr-chemomab-spark-results.pdf

 

CM-101, a monoclonal antibody designed to bind and block CCL24 activity.  The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAM™ mouse model was published in JHEP Reports (A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage - JHEP Reports (jhep-reports.eu)

 

In the future, we believe that further clinical trial results for CM-101 will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.